SEP 2021

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1400530

Contents of this Issue


Page 105 of 106

SUPPLEMENT TO EYEWORLD SEPTEMBER 2021 | 7 Sponsored by Alcon Sponsored by Alcon "Vivity TM is also a great option for the patient desiring increased specta- cle independence but who has other comorbidities that may compromise the optical system such as macular disease or dry eye. "For the type of patients in whom we would normally hesitate to implant a multifocal IOL like the photographer, the radiologist, the painter, or anyone who may have too astute of a visual perception and whose expectations may be unrealistic, this lens is an excellent choice among the advanced IOLs, offering depth of focus with exceptional performance," she said. Patient satisfaction Dr. Shamie hailed the outcomes of both lenses in terms of patient satisfaction. "They deliver on their promise in nearly all patients. The visual aberra- tions expected due to its multifocality are generally not bothersome to the patients and tend to become less notice- able after some time," Dr. Shamie said. When asked on a questionnaire 6 months postop after receiving PanOptix ® , "Given your vision today, if you had to do it all over again, would you have the same lenses implanted again?", 99.2% of patients said they would select PanOptix ® again. 1 Dr. Shamie cited the monofocal-like quality of distance and night vision with Vivity TM in a lens that also allows for "excellent midrange vision without correction." In a survey, 94% and 92% of patients who received a Vivity TM IOL said they had very good or good vision at distance and arm's length, respective- ly, without glasses in bright light. 2 Toric versions of PanOptix ® and Vivity TM expand the pool of candidates seeking increased range of quality vision, reducing the risk of residual refractive error and thus minimizing the need for postop refractive enhance- ments, Dr. Shamie said. "If you have hesitated to implant presbyopia-mitigating IOLs up to now because of concerns around the vision quality or postoperative patient satis- faction, these IOLs are a great option and can offer a successful transition to expand your surgical armamentarium," Dr. Shamie said. "With that said, it is still important to be thoughtful in your patient selection, to optimize the ocular surface as best as possible, to ensure accurate biometry, and to spend the time to educate your patients as to the expected outcomes." Dr. Shamie is a cataract, LASIK, and corneal surgeon and partner at Maloney- Shamie Vision Institute in Los Angeles, California. She can be contacted at ns@maloneyshamie.com. Dr. Shamie considers Vivity TM for patients who might not be a candidate for diffractive multifocal IOLs. Source: Neda Shamie, MD Refer to page 8 for important product information about the Alcon products described in this supplement. Stats and specs PanOptix® Trifocal IOL 20/20 near, intermediate, and distance vision is now possible. *†1 PanOptix® is equipped with advanced ENLIGHTEN® Optical Technology—a proprietary design that optimizes intermediate vision without compromising exceptional near and distance vision. 99.2% of patients would have the same lens implanted again. **††1 Vivity TM IOL Uses X-WAVE ™ technology to stretch and shift light, not split it. Comparable visual disturbance profile to a monofocal IOL 2 94% and 92% of patients who received a Vivity ™ IOL said they had very good or good vision at distance and arm's length, respectively, without glasses in bright light. 2 * Based on mean value of binocular defocus from curve at near, intermediate, and distance at 6 months (n=127). † Snellen VA was converted from logMAR VA. A Snellen notation of 20/20 -2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 Early Treatment Diabetic Retinopathy Study chart letters in the line were identified correctly. ** n=127 †† Response to the following question on IOLSAT questionnaire (Version 10, December 20, 2018) at 6 months' postop: "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?" References 1. AcrySof® IQ PanOptix® Trifocal IOL Directions for Use, 2019 2. AcrySof® IQ Vivity™ Extended Vision IOL Directions for Use, 2020

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - SEP 2021